Norway: manufacture of pharmaceutical products - production value 2020

The production value of the basic pharmaceutical products and pharmaceutical preparations manufacturing industry in Norway decreased to 1.5 billion euros since the previous year. This was the first time during the observed period that the production value in this industry declined in Norway.

The production value is defined as turnover, plus or minus the changes in stocks of finished products, work in progress and goods and services purchased for resale, minus the purchases of goods and services for resale, plus capitalized production, plus other operating income (excluding subsidies). Income and expenditure classified as financial or extra-ordinary in company accounts is excluded from production value.
Find more statistics on the basic pharmaceutical products and pharmaceutical preparations manufacturing industry in Norway with key insights such as turnover.

Production value of the manufacture of basic pharmaceutical products and pharmaceutical preparations in Norway from 2009 to 2020 (in million euros)

Characteristic	Annual production value in million euros
2020p	1,545.5
2019	1,658.8
2013	1,222.9
2009	880

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

February 2022

More information

Region

Norway

Survey time period

2009 to 2020

Supplementary notes

p: Provisional value.
Data from 2010 to 2012 was held confidential by the source.
The source adds the following information: Production value measures the amount actually produced by the unit, based on sales, including changes in stocks and the resale of goods and services. The production value is defined as turnover, plus or minus the changes in stocks of finished products, work in progress and goods and services purchased for resale, minus the purchases of goods and services for resale, plus capitalised production, plus other operating income (excluding subsidies). Income and expenditure classified as financial or extra-ordinary in company accounts is excluded from production value.
Data coverage corresponds to Section C21 of NACE Rev2.

Citation formats